Primary Immunodeficiency Diseases: all 204 studies

Page 1 of 3. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• 25BT056: Basket Study of Viral Cytotoxic T LymphocytesNot yet recruitingNCT07873970Early Phase 1
• Knowledge of Inborn Errors of Immunity Among Pediatric PhysiciansNot yet recruitingNCT07837518
• A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With ImmunoglobulinsNot yet recruitingNCT07794735Phase 4
• Exercise Intervention and ImmunodeficiencyRecruitingNCT07698197Not applicable
• Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant DiseasesNot yet recruitingNCT07660783Phase 2
• Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary ImmunodeficienciesNot yet recruitingNCT07526714
• Immunoglobulin Efficacy and Immune Profiling in Antibody ImmunodeficiencyNot yet recruitingNCT07516002
• Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)RecruitingNCT07346859Phase 3
• Quality of Life Among Children With Inborn Error of ImmunityNot yet recruitingNCT07262047
• Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related DisordersRecruitingNCT07261891Not applicable
• Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID PatientsNot yet recruitingNCT07017036Phase 3
• Shwachman-Diamond Syndrome Global Patient Survey and Partnering PlatformRecruitingNCT06999954
• Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech RepublicAvailableNCT06955793
• Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)RecruitingNCT06669949
• Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center StudyNot yet recruitingNCT06649643
• A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyRecruitingNCT06565078
• Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene ProductsRecruitingNCT06519734
• Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of ImmunityRecruitingNCT06169150
• IVIG Boya: Safety, Efficacy, and PharmacokineticsNot yet recruitingNCT06150833Phase 3
• Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIGNot yet recruitingNCT06089122Phase 3
• Exercise Capacity, Physical Activity Level and Quality of Life in Children With Primary ImmunodeficiencyRecruitingNCT05999422
• Evaluating Bronchodilator Response in Patients With BronchiectasisRecruitingNCT05932316Not applicable
• NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)RecruitingNCT05189925Phase 1
• Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care UnitRecruitingNCT04990908
• Metabolic Profiling of Immune Responses in Immune-mediated DiseasesRecruitingNCT04864886
• Biologics And Clinical Immunology Cohort at SinaiRecruitingNCT04784364
• Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised HostsRecruitingNCT04691622Phase 1
• Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT04528355
• COVID-19 in PID SurveyRecruitingNCT04459689
• TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in ChildrenRecruitingNCT04414046Phase 2
• Pathogenic Study of Adult Immune EnteropathiesRecruitingNCT04280510
• Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow FailuresRecruitingNCT04232085Phase 2
• Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)RecruitingNCT04197596Phase 1/2
• Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary ImmunodeficienciesRecruitingNCT03610802
• Pathophysiology of Inborn ImmunodeficienciesRecruitingNCT03422614
• The Mechanistic Biology of Primary Immunodeficiency DisordersRecruitingNCT03394053
• EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV InfectionRecruitingNCT03266653Phase 2
• Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)RecruitingNCT03266640Phase 2
• Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus InfectionRecruitingNCT03266627Phase 2
• NIAID Centralized Sequencing ProtocolRecruitingNCT03206099
• Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary ImmunodeficienciesRecruitingNCT02735824
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 2
• Studies of Disorders With Increased Susceptibility to Fungal InfectionsRecruitingNCT01222741
• Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation DisordersEnrolling by invitationNCT00895271
• Detection and Characterization of Infections and Infection SusceptibilityRecruitingNCT00404560
• Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell DeathRecruitingNCT00246857
• Genetic Analysis of Immune DisordersRecruitingNCT00001467
• A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency DiseasesCompletedNCT05755035Phase 2/3Results posted
• A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsCompletedNCT05513586Phase 3Results posted
• Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 DepletionActive, not recruitingNCT05236764Not applicableResults posted
• A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)CompletedNCT05150340Phase 3Results posted
• An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseaseCompletedNCT04842643Phase 3Results posted
• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyCompletedNCT04566692Phase 4Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyCompletedNCT04561115Phase 3Results posted
• A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedNCT04346108Phase 3Results posted
• Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency DiseasesCompletedNCT03988426Phase 3Results posted
• Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID PatientsCompletedNCT03961009Phase 3Results posted
• Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesCompletedNCT03939533Phase 3Results posted
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIALCompletedNCT03907241Phase 3Results posted
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/2Results posted
• Primary Immunodeficiency in KuwaitCompletedNCT03618147Results posted
• Bilateral Orthotopic Lung Transplant - Bone Marrow TransplantCompletedNCT03330795Phase 1/2Results posted
• Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD SubjectsCompletedNCT03277313Phase 3Results posted
• Study of PlasmaCap IG in Adults and Children With PIDDCompletedNCT03238079Phase 3Results posted
• Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsCompletedNCT03116347Phase 4Results posted
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)CompletedNCT03033745Phase 4Results posted
• Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDCompletedNCT02810444Phase 3Results posted
• Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02806986Phase 3Results posted
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02604810Phase 3Results posted
• TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PIDCompletedNCT02327351Phase 2/3Results posted
• Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%CompletedNCT02269163Phase 3Results posted
• Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesTerminatedNCT02231710Phase 1Results posted
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/2Results posted
• Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)CompletedNCT01998633Phase 2Results posted
• Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesCompletedNCT01963143Phase 3Results posted
• Study of Octanorm Subcutaneous IG in Patients With PIDCompletedNCT01888484Phase 3Results posted
• Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency DiseasesCompletedNCT01884311Phase 3Results posted
• CD34+ Stem Cell Infusion to Augment Graft FunctionTerminatedNCT01856582Phase 2Results posted
• Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)CompletedNCT01814800Phase 3Results posted
• Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)CompletedNCT01581593Phase 3Results posted
• Tolerability and Safety of IGI, 10% With rHuPH20 in PIDDCompletedNCT01485796Phase 2/3Results posted
• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyCompletedNCT01465958Phase 4Results posted
• Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01458171Phase 3Results posted
• High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)CompletedNCT01313507Phase 3Results posted
• A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary ImmunodeficiencyCompletedNCT01289847Phase 4Results posted
• Phase 2/3 Study of IGSC, 20% in PIDDCompletedNCT01218438Phase 2/3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01199705Phase 3Results posted
• Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PIDCompletedNCT01175213Phase 3Results posted
• A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency DiseasesCompletedNCT01012323Phase 3Results posted
• Gammagard Liquid and rHuPH20 in PIDCompletedNCT00814320Phase 3Results posted
• Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency DiseasesTerminatedNCT00811174Phase 3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)CompletedNCT00751621Phase 3Results posted
• Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)CompletedNCT00719680Phase 3Results posted
• Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric SubjectsCompletedNCT00634569Phase 4Results posted
• Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency DisordersTerminatedNCT00579137Phase 1/2Results posted
• Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) SubjectsCompletedNCT00546871Phase 2/3Results posted
• Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)CompletedNCT00538915Phase 3Results posted
• Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 4Results posted
• Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyCompletedNCT00419341Phase 3Results posted
• A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary ImmunodeficiencyCompletedNCT00389324Phase 2Results posted

← Primary Immunodeficiency Diseases overview